TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: The activity of BV as frontline therapy in some PTCL categories needs to be further investigated, especially given the variability of CD30 expression across subtypes, with the highest levels being found in ALCL and cHL.